California judge rules Allergan, Endo, Johnson & Johnson, and Teva not liable for state's opioid crisis; CDC panel to decide on approval of and recommendations for Pfizer/BioNTech's COVID-19 vaccine in children aged 5 to 11 years; screen time among teenagers more than doubled during the pandemic.
Yesterday, Superior Court Judge Peter J. Wilson of California rejected claims that 4 drug companies—Allergan, Endo, Johnson & Johnson, and Teva—used false and misleading marketing to promote the sale of prescription opioids. Reported by NPR, the ruling indicates that the 4 drug companies cannot be held liable for California’s opioid crisis. If found guilty, they would have had to pay for several costly public health and drug treatment programs. There are several other opioid lawsuits in state and federal courts nationwide, with cases currently underway in New York, Ohio, and West Virginia.
A special advisory panel from the CDC is meeting today to consider recommendations for administering Pfizer/BioNTech’s COVID-19 vaccine in children aged 5 to 11 years, with The Associated Press reporting that the Biden administration, anticipating approval from advisors, is beginning to assemble and ship millions of shots. Delivering a dose that is one-third of the vaccine given to adults, White House Coronavirus Response Coordinator Jeff Zients said the government has enough vaccine for all 28 million young children of the age group. Pending approval, the first shots could be given to children by midweek. Parents will be able to go to vaccines.gov and filter on vaccines for children 5 to 11 to find a location near them that is offering the vaccine.
As reported by USA Today, a study published yesterday in JAMA Pediatrics found that screen time among teenagers outside of virtual school more than doubled from 3.8 hours per day before the pandemic to 7.7 hours per day in 2020. Leveraging data from the Adolescent Brain Cognitive Development Study, the data also show that children of color and those of lower-income families reported greater screen time than their White, wealthier counterparts. Because participants were asked to self-report screen use, wellness experts noted that study projections may be underreported and that estimates are likely greater in teens.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More